Journal Home
Search for

Volume 16, Issue 4, Pages 210-220 (August 2005)


View previous. 4 of 15 View next.

The public health and social impacts of drug market enforcement: A review of the evidence

Thomas KerrabCorresponding Author Informationemail address, Will Smalla, Evan Woodac

Received 27 May 2004; received in revised form 27 April 2005; accepted 28 April 2005.

Abstract 

The primary response to the harms associated with illicit injection drug use in most settings has involved intensifying law enforcement in an effort to limit the supply and use of drugs. Policing approaches have been increasingly applied within illicit drug markets since the 1980s despite limited scientific confirmation of their efficacy. On the contrary, a growing body of research indicates that these approaches have substantial potential to produce harmful health and social impacts, including disrupting the provision of health care to injection drug users (IDU), increasing risk behaviour associated with infectious disease transmission and overdose, and exposing previously unaffected communities to the harms associated illicit with drug use. There are, however, alternatives to traditional targeted enforcement approaches that may have substantially less potential for negative health and social consequences and greater potential for net community benefit. Some of these approaches involve modifying policing practices, fostering partnerships between policing and public health agencies, and developing systems to monitor policing practices. Other alternatives involve the provision of harm reduction services, such as safer injecting facilities, that help to minimize drug-related harms, and addiction treatment services which ultimately help to reduce the demand for illicit drugs.

a British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Burrard Street, Vancouver, BC, Canada V6Z 1Y6

b Canadian HIV/AIDS Legal Network, Canada

c Department of Medicine, University of British Columbia, Canada

Corresponding Author InformationCorresponding author. Tel.: +1 604 806 9116; fax: +1 604 806 9044.

PII: S0955-3959(05)00056-3

doi:10.1016/j.drugpo.2005.04.005


View previous. 4 of 15 View next.